DCGI Approves Corbevax Vaccine For Emergency Use Among 12-18 Age Group

New Delhi: Drugs Controller General of India (DCGI) on Monday approved Biological E’s Covid-19 vaccine Corbevax for emergency use among children aged 12-18 years.

The Hyderabad-based pharmaceutical company’s vaccine had earlier received emergency use authorization from DCGI’s Subject Expert Committee for the 12-18 age group, subject to conditions.

Corbevax, to be administered in two doses, is the third vaccine to be approved for 12-18-year olds in India, the others being Bharat Biotech’s Covaxin and Zydus Cadila’s DNA shot ZyCoV-D.

However, Covaxin is mainly being used currently to inoculate children aged 15-18 years.

Corbevax is expected to cost Rs 145 per dose, excluding taxes, ANI reported quoting sources.

National Technical Advisory Group on Immunisation (NTAGI) chief Dr NK Arora said earlier that Corbevax shots were safe, and offered good immunogenicity and higher antibody levels compared to other vector vaccines.